Adovart slows progress of prostate cancer in clinical trial

A three-year study of 289 men

with prostate cancer showed significantly less progression

of the disease in men taking dutasteride (Avodart) than men receiving a placebo, according to an article in Torder cheap cialis online

/article/PIIS0140-6736(11)61619-X/fulltext” target=”_blank”>he Lancet by doctors who conducted the study.

After three years of observing patients with prostate cancer, the progression rates were 38% for those taking dutasteride and 48% for those taking a placebo.

The difference resulted in a 38% reduction in the hazard for progression. There was no significant difference in the risk of adverse effects between the two groups.

For more information, see the full article online (subscription or $31.50 payment required).

Be Sociable, Share!